Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: together (409), equally (65), mutually (30)

UHS RD Small Grants Scheme 2021_application_form

Description: UHS R&D Small Grants Scheme 2021 University Hospital Southampton NHS Foundation Trust (UHS) R&D is seeking grant applications from investigators
Url: /Media/Southampton-Clinical-Research/Grants/Download/UHS-RD-Small-Grants-Scheme-2021-application-form.docx

UHS AR 23-24 Final

Description: 2023/24 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2023/24 Presente
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-23-24-Final.pdf

Joint Partnership Policy and Guidance on Pre-clinical and Clinical Research Publications

Description: Joint Partnership Policy and Guidance on Pre-clinical and Clinical Research Publications ? ? ? ? Background Scope: who
Url: /Media/Southampton-Clinical-Research/Downloads/Joint-Partnership-Policy-and-Guidance-on-Pre-clinical-and-Clinical-Research-Publications.pdf

Quality account 24-25 final

Description: QUALITY ACCOUNT 2024/25 QUALITY ACCOUNT Contents Part 1: Statement on quality from the chief executive 1.1 Chief executive’s
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/quality-account-24-25-final1.pdf

Cemiplimab

Description: Chemotherapy Protocol SKIN CANCER Cemiplimab (350mg) Regimen  Skin – Cemiplimab (350mg) Indication  Metastatic or locally advanced cutaneous squamous cell carcinoma in p
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Cemiplimab.pdf

UHS Patient safety incident response plan

Description: Patient safety incident response plan Effective date: 2nd October 2023 Estimated refresh date:2nd October 2024 with informal review after the first
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Plans-and-strategies/UHS-Patient-safety-incident-response-plan.pdf

Preparing for your child's heart surgery - patient information

Description: This booklet explains what happens after being placed on the congenital heart surgery referral pathway at Southampton Children's Hospital and contains
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Preparing-for-your-childs-heart-surgery-3363-PIL.pdf

Welcome to Burley ward - patient information

Description: A guide to your stay on Burley ward.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Welcome-to-Burley-ward-2836-PIL.pdf

Nivolumab 240mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab (240mg-14 days) Regimen • NSCLC – Nivolumab (240mg-14days) Indication • Nivolumab monotherapy is recom
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-240mg.pdf

Nivolumab 480mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its market
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf

31 to 40 of 65

Previous … 2 3 4 5 6 … Next